Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Akebia Therapeutics, Inc. (AKBA) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 8-K Quarterly results
09/26/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Akebia Announces Approval of Vafseo® in Australia and Provides Commercial Update"
08/25/2023 8-K Quarterly results
Docs: "Akebia Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights"
08/17/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
Docs: "Akebia Therapeutics to Report Second Quarter Financial Results by August 25, 2023 Akebia Receives Notification of Deficiency from Nasdaq Regarding Late Form 10-Q Filing"
08/11/2023 8-K Quarterly results
08/10/2023 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
08/01/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/01/2023 8-K Quarterly results
07/18/2023 3 Snow Ellen (SVP, CFO and Treasurer) has filed a Form 3 on Akebia Therapeutics, Inc.
07/18/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Akebia Therapeutics Completed Type A Meeting with the FDA and Expects to Resubmit Vadadustat NDA in Third Quarter 2023"
06/13/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/08/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/08/2023 4 ZUMWALT LEANNE M (Director) has filed a Form 4 on Akebia Therapeutics, Inc.
Txns: Granted 30,000 shares @ $0
Granted 45,000 options to buy @ $1.2, valued at $54k
06/08/2023 4 ROGERS MICHAEL W (Director) has filed a Form 4 on Akebia Therapeutics, Inc.
Txns: Granted 30,000 shares @ $0
Granted 45,000 options to buy @ $1.2, valued at $54k
06/08/2023 4 FRIESON RON (Director) has filed a Form 4 on Akebia Therapeutics, Inc.
Txns: Granted 30,000 shares @ $0
Granted 45,000 options to buy @ $1.2, valued at $54k
06/08/2023 4 Wolf Myles (Director) has filed a Form 4 on Akebia Therapeutics, Inc.
Txns: Granted 30,000 shares @ $0
Granted 45,000 options to buy @ $1.2, valued at $54k
06/08/2023 4 ADAMS ADRIAN (Director) has filed a Form 4 on Akebia Therapeutics, Inc.
Txns: Granted 30,000 shares @ $0
Granted 45,000 options to buy @ $1.2, valued at $54k
06/08/2023 4 Smith Cynthia (Director) has filed a Form 4 on Akebia Therapeutics, Inc.
Txns: Granted 30,000 shares @ $0
Granted 45,000 options to buy @ $1.2, valued at $54k
06/08/2023 4 GILMAN STEVEN C (Director) has filed a Form 4 on Akebia Therapeutics, Inc.
Txns: Granted 30,000 shares @ $0
Granted 45,000 options to buy @ $1.2, valued at $54k
06/07/2023 8-K Investor presentation
Docs: "Commercial Depth. Operational Excellence. A Commitment to Advance Innovation to Address Unmet Needs. John P. Butler, CEO June 2023 Exhibit 99.1"
06/06/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
06/02/2023 8-K Other Events  Interactive Data
05/31/2023 8-K Regulation FD Disclosure  Interactive Data
05/25/2023 4 Hadas Nicole R. (SVP, Chief Legal Officer) has filed a Form 4 on Akebia Therapeutics, Inc.
Txns: Granted 200,000 shares @ $0
Sold 63,186 shares @ $1.2229, valued at $77.3k
Granted 200,000 options to buy @ $0.41, valued at $82k
05/25/2023 4 Dahan Michel (SVP, COO) has filed a Form 4 on Akebia Therapeutics, Inc.
Txns: Granted 200,000 shares @ $0
Sold 95,478 shares @ $1.2229, valued at $116.8k
Granted 200,000 options to buy @ $0.41, valued at $82k
05/25/2023 144 Form 144 - Report of proposed sale of securities:
05/25/2023 144 Form 144 - Report of proposed sale of securities:
05/25/2023 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "Akebia Therapeutics Enters into License Agreement with Medice Arzneimittel Pütter GmbH&Co.KG for the Commercialization of Vafseo® for the Treatment of Anemia associated with CKD in Europe and Australia"
05/23/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Akebia Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement"
05/18/2023 4 Burke Steven Keith (SVP, Chief Medical Officer) has filed a Form 4 on Akebia Therapeutics, Inc.
Txns: Sold 63,567 shares @ $1.068, valued at $67.9k
05/18/2023 4 Spellman David A (SVP, CFO and Treasurer) has filed a Form 4 on Akebia Therapeutics, Inc.
Txns: Sold 63,567 shares @ $1.068, valued at $67.9k
05/16/2023 144 Form 144 - Report of proposed sale of securities:
05/16/2023 144 Form 144 - Report of proposed sale of securities:
05/16/2023 4 Hadas Nicole R. (SVP, Chief Legal Officer) has filed a Form 4 on Akebia Therapeutics, Inc.
Txns: Granted 100,000 shares @ $0
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy